Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer

Phase 2

Completed

Conditions: Peritoneal Cavity Cancer
Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Procedure: debulking surgery

First Posted Date: 2003-01-27

Last Posted Date: 2016-01-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 62

Registration Number: NCT00008138

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2020-09-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 58

Registration Number: NCT00049257

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: Docetaxel
Biological: trastuxumab
Drug: carboplatin

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 263

Registration Number: NCT00047255

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

Phase 2

Completed

Conditions: Central Nervous System Tumor
Brain Tumor

Interventions: Radiation: radiation therapy
Biological: filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: vincristine sulfate
Drug: Mesna
Procedure: therapeutic conventional surgery

First Posted Date: 2003-01-27

Last Posted Date: 2019-08-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 378

Registration Number: NCT00027846

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Advocate Christ Medical Center, Oak Lawn, Illinois, United States

and more 161 locations

ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.

Phase 2

Completed

Conditions: Lung Neoplasms

First Posted Date: 2003-01-14

Last Posted Date: 2006-07-20

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00051506

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Charleston, South Carolina, United States